A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells.
Liu Y, Jie X, Nian L, Wang Y, Wang C, Ma J, Jiang J, Wu Q, Qiao J, Chen W, Cao J, Yan Z, Shi M, Cheng H, Zhu F, Sang W, Li D, Chen C, Xu K, Li Z.
Liu Y, et al. Among authors: wang y, wang c.
Front Immunol. 2023 Apr 19;14:1169071. doi: 10.3389/fimmu.2023.1169071. eCollection 2023.
Front Immunol. 2023.
PMID: 37153543
Free PMC article.